Literature DB >> 15606355

Preventative and therapeutic vaccines for fungal infections: from concept to implementation.

George S Deepe1.   

Abstract

Many challenges confront the development of fungal vaccines for humans including differences in host susceptibility, varied pathogenic mechanisms employed by the different species of fungi and mechanisms of host resistance. Hence, no single antigen can be expected to serve as a pan fungal vaccine. Instead, it is likely that progress for fungal vaccines will have to be made at the level of each individual organism. In recent years, tremendous strides have been made in understanding the immunopathogenesis of medically important fungal infections and identifying putative vaccine candidates. Such discoveries will facilitate the introduction of fungal vaccines into the therapeutic armamentarium of clinicians. The fungi under discussion in this review include Candida spp., Aspergillus spp., Cryptococcus neoformans, Coccidioides spp., Histoplasma capsulatum, Blastomyces dermatitidis, Paracoccidioides brasiliensis and Pneumocystis jirovecii.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15606355     DOI: 10.1586/14760584.3.6.701

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  14 in total

Review 1.  [Therapeutic or prophylactic antifungal vaccination: problems and solutions].

Authors:  S Boneberger; H C Korting
Journal:  Hautarzt       Date:  2008-10       Impact factor: 0.751

2.  Interleukin 1 enhances vaccine-induced antifungal T-helper 17 cells and resistance against Blastomyces dermatitidis infection.

Authors:  Marcel Wüthrich; Vanessa LeBert; Kevin Galles; Jane Hu-Li; Shlomo Z Ben-Sasson; William E Paul; Bruce S Klein
Journal:  J Infect Dis       Date:  2013-06-20       Impact factor: 5.226

3.  Vaccines to prevent systemic mycoses: holy grails meet translational realities.

Authors:  John N Galgiani
Journal:  J Infect Dis       Date:  2008-04-01       Impact factor: 5.226

4.  Blastomyces dermatitidis yeast cells inhibit nitric oxide production by alveolar macrophage inducible nitric oxide synthase.

Authors:  Nicole M Rocco; John C Carmen; Bruce S Klein
Journal:  Infect Immun       Date:  2011-03-28       Impact factor: 3.441

Review 5.  Recent advances in our understanding of the environmental, epidemiological, immunological, and clinical dimensions of coccidioidomycosis.

Authors:  Chinh Nguyen; Bridget Marie Barker; Susan Hoover; David E Nix; Neil M Ampel; Jeffrey A Frelinger; Marc J Orbach; John N Galgiani
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

Review 6.  Advances in combating fungal diseases: vaccines on the threshold.

Authors:  Jim E Cutler; George S Deepe; Bruce S Klein
Journal:  Nat Rev Microbiol       Date:  2006-12-11       Impact factor: 60.633

7.  Mice immunization with radioattenuated yeast cells of Paracoccidiodes brasiliensis: influence of the number of immunizations.

Authors:  Estefânia Mara do Nascimento Martins; Bernardo Sgarbi Reis; Maria Aparecida de Resende; Antero Silva Ribeiro de Andrade; Alfredo Miranda Goes
Journal:  Mycopathologia       Date:  2009-04-07       Impact factor: 2.574

8.  Endemic mycoses in immunocompromised hosts.

Authors:  Trent R Malcolm; Peter V Chin-Hong
Journal:  Curr Infect Dis Rep       Date:  2013-12       Impact factor: 3.725

9.  Adjuvanticity of a recombinant calreticulin fragment in assisting anti-β-glucan IgG responses in T cell-deficient mice.

Authors:  Wei-Ji Li; Kai Long; Hong-Liang Dong; Xiao-Ming Gao
Journal:  Clin Vaccine Immunol       Date:  2013-02-13

10.  Vaccine-induced protection against 3 systemic mycoses endemic to North America requires Th17 cells in mice.

Authors:  Marcel Wüthrich; Benjamin Gern; Chiung Yu Hung; Karen Ersland; Nicole Rocco; John Pick-Jacobs; Kevin Galles; Hanna Filutowicz; Thomas Warner; Michael Evans; Garry Cole; Bruce Klein
Journal:  J Clin Invest       Date:  2011-01-04       Impact factor: 19.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.